Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission

Table 3

Duration of disease in patients with Graves’ disease, type 2 deiodinase gene Thr92Ala polymorphism genotypes.

	D2 gene genotypes			𝑃
	T/T (𝑛=106)	A/T (𝑛=60)	A/A (𝑛=14)
Total duration of the disease (months)	32.2 (7.9; 131.8)	16.8 (4.2; 67.1)	14.0 (5.6; 35.2)	0.007
Duration of overt thyrotoxicosis (months)	15.5 (5.9; 40.6)	10.9 (4.8; 25.0)	10.0 (4.2; 24.1)	0.04